Primary endpoint showed clinically meaningful improvement in patients with SMA receiving apitegromab as measured by gold standard Hammersmith Functional Motor Scale Expanded (HFMSE) versus placebo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback